BioSpace

How can startup leaders support long-term sustainable growth and investment?

BioSpace’s Lori Ellis speaks with venture capital guests Ansbert Gadicke, Martin Gershon and Mike Goguen for their advice and recommendations on how biopharma startups should approach funding.

Host 

⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠, Head of Insights, BioSpace  

Guests

⁠Ansbert Gadicke⁠, Managing Director, MPM Capital

⁠Martin Gershon⁠, Managing Partner & CIO, Endeavor Venture Fund

⁠Mike Goguen⁠, Founder and Managing Partner, Two Bear Capital 

Biden administration flexes regulatory muscles, putting pressure on the biopharma industry over ‘price gouging’ and invoking march-in rights; meanwhile Sanofi throws in towel over threat of injunction 

Renewed interest in psychedelics after MindMed’s Phase IIb trial of its LSD-based candidate meets primary endpoint in patients with generalized anxiety disorder.  

Bluebird bio changes its tune, signing an ‘outcomes- based’ agreement with commercial payer, and Pfizer struggles continue.

BioSpace's Lori Ellis, Greg Slabdodkin and Tyler Patchen discuss.

And that's a wrap on 2023! We'll see you in the New Year.

What needs to happen for funding in biopharma to bounce back? BioSpace’s Lori Ellis discusses the macroeconomic environment and biopharma funding outlook with venture capital guests Ansbert Gadicke, Martin Gershon and Mike Goguen. 

Host 

⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠, Head of Insights, BioSpace  

Host 

⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpace  

Guests

⁠⁠Ansbert Gadicke⁠⁠, Managing Director, MPM Capital

⁠⁠Martin Gershon⁠⁠, Managing Partner & CIO, Endeavor Venture Fund

⁠⁠Mike Goguen⁠⁠, Founder and Managing Partner, Two Bear Capital 

That was Week with a capital W. Two major FDA approvals for sickle cell came through on Friday - Casgevy, the first-ever CRISPR-based gene editing therapy from Vertex and CRISPR Therapeutics, and bluebird bio’s Lyfgenia, which comes with a hefty price tag and a black box warning. 

Axcella announced its closure; what does the future of long-covid treatments look like, especially as attention shifts to different markets like ADCs and neurological treatments? 

Also discussed - Vanda drops $100m on rights to MS drug Ponvory, AI regulatory developments in Europe. 

BioSpace's Lori Ellis, Greg Slabodkin and Tyler Patchen discuss.

This is the second part of our discussion on the evolution of artificial intelligence and its impact on life sciences with guests from Microsoft and IQVIA.

We dive into regulation, real-time management, and AI's various applications and how it can streamline different processes.

We also discuss the cost and affordability of AI; the tremendous investment required and when holding off on new tech is valuable.

Hear how AI is highlighting society's flaws and may become the catalyst for societal change.

Host 

⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠, Head of Insights, BioSpace  

Guests 

⁠Matt O’Donnell⁠, Industry Executive Health & Life Sciences, Microsoft 

⁠⁠⁠Mike King⁠⁠⁠⁠, Senior Director of Product and Strategy, IQVIA 

Over the last year, the reaction to generative AI has changed - and so have behaviors. People are integrating AI to become more productive and it is happening now in healthcare and life sciences. Hear from senior leaders at Microsoft and IQVIA to get their take on how generative AI is impacting productivity, employee engagement and how to mitigate risks. 

Host 

⁠⁠⁠Lori Ellis⁠⁠⁠, Head of Insights, BioSpace  

Guests 

Matt O’Donnell, Industry Executive Health & Life Sciences, Microsoft 

⁠⁠Mike King⁠⁠⁠, Senior Director of Product and Strategy, IQVIA 

The weight loss market sees more ups and downs - Altimmune joins the fray and sees a stock jump while Pfizer experiences setbacks; and European Medicines Agency seeks additional information as part of its ongoing review of the potential risk of suicide and self-harm thoughts associated with the class. Meanwhile, AbbVie buys ImmunoGen for a cool $10B and scores a win with Teliso-V as ADC momentum continues to build.

Plus, the FDA investigates malignacies linked to CAR-T.

BioSpace's Lori Ellis, Greg Slabodkin and Tyler Patchen discuss.

Patient behavior has always had an influence on clinical trials - so how do we contend with missing and/or irregular data now that it is feeding AI models? And how do providers continue to work with patients to optimize and grow data pools?

This is the third and final part of a discussion focused upon data bias, accuracy, access and the future of AI in drug development.

Host 

⁠⁠Lori Ellis⁠⁠, Head of Insights, BioSpace  

Guests 

⁠⁠Paul Agapow⁠⁠, Director of Innovation, Data Science and Strategy, GlaxoSmithKline⁠⁠⁠

⁠Mike King⁠⁠, Senior Director of Product and Strategy, IQVIA 

⁠⁠Nindhana Paranthaman⁠⁠, Executive Medical Director, Exelixis 

⁠⁠Moritz von Stosch⁠⁠, Chief Information Officer, DataHow 

The breadth of AI in healthcare applications is broad. How much human oversight is necessary or preferred when leveraging AI in the interest of patient safety?

Listen to this in-depth discussion on how AI can help identify end-to-end data weaknesses, as well as broader implications regarding the inevitability of human interaction.

This is part two of a discussion focused upon data bias, accuracy, access and the future of AI in drug development.

Host 

⁠Lori Ellis⁠, Head of Insights, BioSpace  

Guests 

⁠Paul Agapow⁠, Director of Innovation, Data Science and Strategy, GlaxoSmithKline⁠

Mike King⁠, Senior Director of Product and Strategy, IQVIA 

⁠Nindhana Paranthaman⁠, Executive Medical Director, Exelixis 

⁠Moritz von Stosch⁠, Chief Information Officer, DataHow 

This week we talk struggles with GLP-1 drug shortages and what that might mean for Novo/Lilly competitors; Regeneron and Sanofi positive results for ⁠⁠Dupixent⁠⁠ in COPD.

Plus, Merck buys Caraway, Beigene's deal with Ensem, ups and downs for Flagship.

Join BioSpace's Lori Ellis, Greg Slabodkin and Tyler Patchen as they discuss the most important biopharma news this week.